This might be a wonderful entry point for long-term investors.

Novo Nordisk ( NVO 3.84% ) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone.

Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why.

The weight management opportunity

Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced

See Full Page